Real‐world effectiveness of vedolizumab compared to<scp>anti‐TNF</scp>agents in biologic‐naïve patients with ulcerative colitis: A two‐year propensity‐score‐adjusted analysis from the prospective, observational<scp>VEDO<sub>IBD</sub></scp>‐study
Bernd Bokemeyer, Sandra Plachta‐Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Thomas Krause, Martin Hoffstadt, Robert Ehehalt, Leo Trentmann, Axel Schweitzer, Petra Jessen, Petra Hartmann, Stefan Schreiber
Abstract
BACKGROUND: registry study. AIM: To compare the effectiveness of vedolizumab and anti-TNF agents in biologic-naïve patients with ulcerative colitis (UC) at the end of induction and during maintenance treatment. METHODS: Between 2017 and 2020, we enrolled 512 patients with UC starting therapy with vedolizumab or an anti-TNF agent in 45 IBD centres across Germany. We excluded biologic-experienced patients and those with missing partial Mayo (pMayo) outcomes; this resulted in a final sample of 314 (182 on vedolizumab and 132 on an anti-TNF agent). The primary outcome was clinical remission measured using pMayo score; any switch to a different biologic agent was considered an outcome failure (modified ITT analysis). We used propensity score adjustment with inverse probability of treatment weighting to correct for confounding. RESULTS: During induction therapy, clinical remission was relatively low and similar in vedolizumab- and anti-TNF-treated patients (23% vs. 30.4%, p = 0.204). However, clinical remission rates after two years were significantly higher for vedolizumab-treated patients than those treated with an anti-TNF agent (43.2% vs. 25.8%, p < 0.011). Among patients treated with vedolzumab, 29% switched to other biologics, versus 54% who had received an anti-TNF agent. CONCLUSION: After two years of treatment, vedolizumab resulted in higher remission rates than anti-TNF agents.